Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,522.92
(
0.30%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: acgood post# 131917

Monday, 11/28/2011 11:20:27 AM

Monday, November 28, 2011 11:20:27 AM

Post# of 257302

I was reading the transcript of the MRK r&d day from november, it has a good outline of their thoughts on biosimilars. Do you think they'll change their plans at all with the announcement of the new enbrel patent?

MRK may have anticipated the issuance of this patent and kept mum for competitive reasons. If not, they have a problem in the US market but could still sell the Enbrel FoB elsewhere.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today